Kim Newcomer, director of volunteers, Colorectal Cancer Alliance, discusses a study conducted with Takeda and the Harris Poll ...

Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...

Researchers discovered the importance of an enzyme that promotes growth of certain lung cancers. Lung cancer is a ...

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research.

Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, ...

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

Ma-Yi Theater Company and The Public Theater are set to bring the intense world of sumo wrestling to the stage with the New ...

When medical interventions fail, melanocyte keratinocyte transplantation may be the most advanced procedural option for ...

Bain Capital has agreed to acquire Mitsubishi Chemical Group's pharmaceutical business for more than $3 billion, a deal that would allow the Japanese company to focus on its key chemical businesses.

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while ...